Clinical and molecular factors that impact the efficacy of first-line crizotinib in ROS1-rearranged non-small-cell lung cancer: a large multicenter retrospective study
Sign Up to like & getrecommendations! Published in 2021 at "BMC Medicine"
DOI: 10.1186/s12916-021-02082-6
Abstract: ROS1-rearranged lung cancers benefit from first-line crizotinib therapy; however, clinical and molecular factors that could affect crizotinib efficacy in ROS1-rearranged lung cancers are not yet well-elucidated. Our retrospective study aimed to compare the efficacy of… read more here.
Keywords: first line; line crizotinib; ros1 rearranged; line ... See more keywords